Every 424B that EUDA Health Holdings Limited (EUDA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow EUDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EUDA filings page.
EUDA Health Holdings Limited has filed a resale prospectus covering up to 947,963 ordinary shares, including 7,306 shares issuable upon exercise of 292,250 warrants. All shares may be sold from time to time by existing shareholders; the company is not selling shares and will not receive resale proceeds.
The registered shares include 500,000 shares issued under a Simple Agreement for Future Tokens with QB Limited and shares held by affiliates. Ordinary shares outstanding were 2,994,325 as of July 31, 2026, or 3,001,631 assuming full exercise of the registered warrants.
EUDA distributes non-invasive healthcare products and property management services in Asia and is developing a digital health and rewards platform integrating QB Utility Tokens. EUDA discloses recurring losses, a going concern explanatory paragraph, and a material weakness in internal control over financial reporting, alongside extensive risks related to token integration, reliance on third parties, regulation and capital needs.
Euda Health Holdings Limited reports that it has terminated its at-the-market equity offering program and the related At The Market Offering Agreement with Chardan Capital Markets, LLC. The program had previously allowed sales of ordinary shares with an aggregate offering price of up to $10.0 million, but this capacity had been reduced to zero and no ordinary shares were sold. All related prospectus supplements are also terminated as of the date of this supplement. The company’s ordinary shares trade on the NASDAQ Capital Market under the symbol EUDA, and the closing price was $15.30 on July 21, 2026.
EUDA Health Holdings filed a prospectus supplement to amend its prior ATM registration, reducing the maximum aggregate offering price to $10.0 million and suspending further sales under the ATM Agreement. The company states that no ordinary shares have been sold under the ATM Agreement as of the date of this Supplement. The company notified the manager on June 5, 2026 of its intent to terminate the ATM Agreement; the termination becomes effective 30 business days after that notice per the agreement. The supplement notes the Nasdaq closing price of the ordinary shares was $15.50 on June 11, 2026.
EUDA Health is registering 12,500,000 ordinary shares in a registered direct offering. The offering is being made pursuant to Securities Purchase Agreements dated February 24 and 25, 2026 and is being issued directly to accredited investors without a placement agent.
The company estimates net proceeds of approximately $3,692,000. As of the date of this Prospectus Supplement there were 37,807,491 Ordinary Shares outstanding; the company states there will be 50,307,491 Ordinary Shares issued and outstanding after this offering. The Ordinary Shares trade on Nasdaq under the symbol EUDA; the cited closing price on February 27, 2026 was $0.9747.
EUDA Health Holdings Limited has filed a 2026 prospectus supplement for its existing at-the-market equity program, allowing it to sell ordinary shares with an aggregate offering price of up to $10,000,000 through Chardan Capital Markets as sales agent. The company states that no ordinary shares have been sold under this Sales Agreement to date.
The supplement highlights business risks, including uncertainty around plans to work with third parties to establish a longevity clinic in Shenzhen, China, for which no binding agreements or approvals currently exist. It also notes uncertainty around launching an integrated digital health and rewards platform and the future use of QB coin utility cryptocurrency, which is still in development by a third party. EUDA cautions that failure of these initiatives could materially and adversely affect its business and results of operations.
EUDA Health Holdings Limited is updating its prospectus for up to 2,000,000 ordinary shares issuable under a convertible warrant, reflecting new terms agreed with Streeterville Capital.
The Second Warrant Amendment cuts the exercise price from $4.00 to $2.00 per share and lowers the Nasdaq price needed for a “Forced Exercise” from $6.00 to $3.00, while the warrant remains unexercised. The company warns it is more likely than not that a large number of shares could be issued to the investor for no additional consideration if cash exercises or Forced Exercise conditions are not met, which would dilute other holders.
Assuming full cash exercise, EUDA estimates net proceeds of about $4.1 million, with $2.2 million earmarked for marketing and the balance for general corporate purposes and potential acquisitions. The company discloses that as of June 30, 2025, the transaction would increase net tangible book value per share from $(0.11) to $0.01, while implying dilution of $1.99 per share to new investors at the $2.00 price.
EUDA Health Holdings Limited has filed a prospectus supplement to end its continuous offering of Convertible Promissory Notes and the Ordinary Shares issuable upon their conversion under a prior prospectus. The company had the ability to issue up to US$10,000,000 of Convertible Notes and previously registered up to 5,000,000 Ordinary Shares for issuance upon conversion; as of this supplement it has sold Convertible Notes with an aggregate principal amount of $1,000,000 and issued 692,729 Ordinary Shares to the investor upon conversion. No additional Convertible Notes will be sold and no further shares will be issued under that note program. Separately, EUDA maintains a shelf registration allowing it to offer up to $100,000,000 of ordinary shares, warrants, subscription rights, debt securities and units over time. The filing also highlights the $15.0 million share-based acquisition of CK Health, for which EUDA issued 8,571,428 shares and later recognized a $14,762,562 impairment on related intangible assets, and notes that a significant shareholder holds demand registration rights for the 8,571,428 shares.